IMMUNE RESPONSE CORP
10-Q, EX-27, 2000-11-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: IMMUNE RESPONSE CORP, 10-Q, EX-10.76, 2000-11-14
Next: ADVANCED POLYMER SYSTEMS INC /DE/, 10-Q, 2000-11-14



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED BALANCE SHEETS AND CONSOLIDATED STATEMENTS OF OPERATIONS
EXTRACTED FROM ITEM 1 OF FORM 10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2000 AND
YEAR-TO-DATE AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                           8,428
<SECURITIES>                                    26,924
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                35,774
<PP&E>                                          18,465
<DEPRECIATION>                                   9,557
<TOTAL-ASSETS>                                  49,944
<CURRENT-LIABILITIES>                            3,933
<BONDS>                                              0
                            9,837
                                          0
<COMMON>                                            75
<OTHER-SE>                                      30,289
<TOTAL-LIABILITY-AND-EQUITY>                    49,944
<SALES>                                              0
<TOTAL-REVENUES>                                 7,889
<CGS>                                                0
<TOTAL-COSTS>                                   19,202
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 228
<INCOME-PRETAX>                               (11,313)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (11,313)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (11,313)
<EPS-BASIC>                                      (.44)
<EPS-DILUTED>                                    (.44)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission